Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $1.13, $0.08 better than the analyst estimate of $1.05. Revenue for the quarter came in at $616.8 million versus the consensus estimate of $604.97 million.

"Strong performance this quarter was boosted by growing global TAVR therapy adoption, with our transcatheter heart valves posting impressive growth," said Michael A. Mussallem, chairman and CEO. "We are now underway with the U.S. launch of our most advanced SAPIEN 3 transcatheter heart valve, which has demonstrated improved outcomes for patients suffering from severe, symptomatic aortic stenosis."

Edwards Lifesciences sees FY2015 EPS of $4.30-$4.40, versus prior guidance of $4.10-$4.30 and the consensus of $4.28. Edwards Lifesciences sees FY2015 revenue of $2.3-2.5 billion, versus the consensus of $2.41 billion.

Edwards Lifesciences sees FY2015 EPS of $0.92-$1.00, versus the consensus of $0.98. Edwards Lifesciences sees FY2015 revenue of $580-620 million, versus the consensus of $587.1 million.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.